Training Series – Quality in Clinical Research

Published on December 14, 2023

Do you want to learn more about the implemented ICH E8(R1) General Considerations in Clinical Trials document and the upcoming change in regulations pertaining to the ICH E6(R3) Good Clinical Practice?

Join us in a training series which focuses on ICH E8(R1), the revised international guidance for best practices on designing, conducting and reporting clinical trials. Learn how to apply the principles of quality by design and quality management systems to your studies.

The series consists of four one-hour sessions, each covering a different topic:

 

  • ICH E8(R1) General Considerations in Clinical Trials: Jan 16, 12 – 1 p.m. Learn more.
  • Quality by Design (QbD) and Critical to Quality (CTQ) Factors: Jan 18, 12 – 1 p.m. Learn more.
  • Risk management for clinical trial sites: Jan 23, 12 – 1 p.m. Learn more.
  • Quality management systems (QMS) overview: Jan 25, 12 – 1 p.m. Learn more.

Don’t miss this opportunity to update your knowledge on the international best practices and quality requirements for clinical trials and the implications for research teams in BC.

Original source here.

The post Training Series – Quality in Clinical Research appeared first on Life Sciences British Columbia.

Continue reading on website
Other news

After long-running patent battle, Vertex pays $100M to license Editas’ gene-editing tech

December 14, 2023
After receiving the FDA greenlight for its sickle cell disease (SCD) gene therapy, Vertex Pharmaceuticals is paying up to $100 million—plus potential licensing fees—for rights to Editas Medicines’ Cas9 gene-editing tech, a deal that encompasses freshly approved Casgevy.Under the new deal, Vertex secures non-exclusive licensing rights to Editas’ Cas9 tech for ex vivo gene-editing medicines targetin

Pfizer Completes Acquisition of Seagen

December 18, 2023
NEW YORK– Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.“Cancer rem